Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376382 | 0.81 | HTR3A (1.00) | HTR3AHRH3KCNH2 | |
| SCHEMBL4055271 | 0.80 | LMNA (0.55) | HTR3AHRH3KCNH2DRD1ALDH1A1 | |
| SCHEMBL1372708 | 0.80 | LMNA (0.55) | HTR3AHRH3KCNH2DRD1ALDH1A1 | |
| SCHEMBL1373480 | 0.77 | HTR3A (1.00) | HTR3AHRH3KCNH2 | |
| SCHEMBL1373478 | 0.77 | HTR3A (1.00) | HTR3AHRH3KCNH2 | |
| SCHEMBL4064118 | 0.76 | HTR3A (0.58) | HTR3AHRH3KCNH2 | |
| SCHEMBL3610358 | 0.75 | HTR3A (0.71) | HTR3AHRH3KCNH2CYP19A1ADORA2A | |
| SCHEMBL3604079 | 0.74 | HRH3 (0.66) | HTR3AHRH3KCNH2CYP1A2CYP2D6 | |
| SCHEMBL8482163 | 0.74 | JAK2 (0.53) | HTR3AHRH3KCNH2CYP1A2ALDH1A1 | |
| SCHEMBL1376653 | 0.73 | HTR3A (0.65) | HTR3AHRH3KCNH2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| CN-101522638-A | Pyridizinone derivatives | CEPHALON INC (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-2069312-A2 | PYRIDIZINONE DERIVATIVES | Cephalon, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | HTR3A 347/4885HRH3 4/4885KCNH2 2381/4885 |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | HTR3A 17/4885HRH3 1/4885KCNH2 2825/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HTR3A 15/4885HRH3 1/4885KCNH2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.